|
Post by jpg on Apr 25, 2015 21:19:44 GMT -5
My big question in all this is where do they get the money to do all these drug developments independently? If only they'd announce some sort of deal where the other company pays all the R&D costs and we just end up getting a XX% royalty. Doing small phase 1 trials of whatever they want to move forward on is relatively cheap and fast and can be done without a partner but for anything past that they need real $. This may sound heretic but I am in no particular hurry for them to announce deals unless they are good deals that gives them real $ and good profit sharing. Yes announcing 1 or 2 deals soon could help share price but I think Afrezza will eventually do that on it's own and that once Afrezza starts selling we will be in a much better position to get multiple good deals.
|
|
|
Post by tigiron on Apr 26, 2015 2:43:35 GMT -5
Hakan Edstrom: But importantly, we've already identified the area of development of the specific API and disease indication for each, and some key hires are also part of the plan."Are they required to make announcement about those key hires?
|
|
|
Post by biotec on Apr 26, 2015 5:09:44 GMT -5
If only they'd announce some sort of deal where the other company pays all the R&D costs and we just end up getting a XX% royalty. Doing small phase 1 trials of whatever they want to move forward on is relatively cheap and fast and can be done without a partner but for anything past that they need real $. This may sound heretic but I am in no particular hurry for them to announce deals unless they are good deals that gives them real $ and good profit sharing. Yes announcing 1 or 2 deals soon could help share price but I think Afrezza will eventually do that on it's own and that once Afrezza starts selling we will be in a much better position to get multiple good deals. I agree, Theres no rush until afrezza is a household name. Ill wait for a great deal/partner then rush into a bad deal. Also issuing more stock at this time would suck!
|
|
|
Post by als57 on Apr 26, 2015 9:03:52 GMT -5
Haken is "blowing smoke!" Mannkind's best shot at developing additional Technosphere medications is to go for a change of control and have Sanofi "pony up" and buy Afrezza and the GLP-1 content, or, and I feel certain, that there is one or more BP's waiting in the wings. Once the transaction is complete there will be adequate funding for Technosphere projects, either in partnership or limited going it alone.
I maybe disappointed, but I suspect that the "bread crumbs" of gleaned info, are leading to a Buy Out. Example: the exec's are loading their pockets with cheap options, with the package to be voted on at the annual meeting in Danbury. Between Mr. Mann, his foundation shares and options and the do-nothing execs, the New Jersey office being sold or abandoned, Sanofi requesting its shareholders for approval of usning 7,000,000 shares for future acquisition/s. The bread crumbs are doing the pointing!
|
|